CFRX ContraFect Corporation

2.15
+0.15  (7.5%)
Previous Close 2.00
Open 2.05
Price To book 4.48
Market Cap 89.39M
Shares 41,578,000
Volume 97,549
Short Ratio 5.43
Av. Daily Volume 36,711

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced January 6, 2017 that its Phase 2 trial initiation has been delayed until mid-2017. Previous guidance was for 4Q 2016.
CF-301
Serious infections caused byStaph aureus including MRSA

Latest News

  1. CONTRAFECT CORP Files SEC form 8-K, Change in Directors or Principal Officers
  2. Lisa Ricciardi to Join Board of Directors
  3. CONTRAFECT CORP Financials
  4. ContraFect Provides Program Update
  5. ContraFect Provides Program Update
  6. ContraFect to Present at Biotech Showcase 2017 Conference
  7. Is ContraFect Corp (CFRX) A Good Stock To Buy?
  8. ContraFect Corp. :CFRX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  9. Greenwood Hall Announces Appointment of Rubinstein, Sucoff, and Poutre to Board of Directors
  10. The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3
  11. ContraFect to Present at 28th Annual Piper Jaffray Healthcare Conference
  12. ContraFect Awarded $2.1 Million PRMRP Grant to Support Development of CF-301
  13. CFRX: Preparations Continue for Launch of Phase 2 Clinical Trial of CF-301 in 4Q16…
  14. ContraFect Announces Expanded Research Collaboration with The Rockefeller University to Identify Lysin Therapeutics Targeting Gram-negative Bacteria
  15. ContraFect to Present at The Lysin Meeting
  16. CONTRAFECT CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  17. CONTRAFECT CORP Files SEC form 10-Q, Quarterly Report
  18. ContraFect Reports Third Quarter 2016 Financial Results and Provides Business Update
  19. ContraFect Reports Third Quarter 2016 Financial Results and Provides Business Update
  20. CONTRAFECT CORP Files SEC form 8-K, Change in Directors or Principal Officers